The Max Foundation, a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally, will launch access to the Novartis therapy Scemblix (asciminib) in 36 low- and middle-income countries in 2023 for people living with chronic myeloid leukemia as part of the CancerPath to Care collaboration with Novartis.
One of the great pleasures of summer is having more time to read.
